跳至主要内容
临床试验/NCT00077129
NCT00077129已完成2 期

Phase II Trial Of Paclitaxel Plus Carboplatin In Patients With Metastatic Or Locally Advanced Collecting Duct Renal Cell Cancer

Eastern Cooperative Oncology Group70 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2006年6月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
22
试验地点
70
主要终点
Proportion of patients with clinical response

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving paclitaxel together with carboplatin works in treating patients with locally advanced or metastatic collecting duct renal cell cancer that cannot be removed by surgery.

详细描述

OBJECTIVES:

Primary

  • Determine the response rate in patients with locally advanced or metastatic collecting duct renal cell cancer treated with paclitaxel and carboplatin.

Secondary

  • Determine the tolerability of this regimen in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Proportion of patients with clinical response

次要结局

  • Toxicity

研究者

申办方类型
Network

研究点 (70)

Loading locations...

相似试验